DYN Dyne Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DYN

Price (delayed)

$13.43

Market cap

$783.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.32

Enterprise value

$629.44M

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in ...

Highlights
The debt is down by 9% year-on-year and by 2.4% since the previous quarter
Dyne Therapeutics's quick ratio has increased by 21% from the previous quarter but it has decreased by 20% YoY
The equity has contracted by 28% YoY and by 4.1% from the previous quarter
DYN's net income is down by 11% YoY and by 5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.dyne-tx.com
Peers: NRG AES ALE CNP

Key stats

What are the main financial stats of DYN
Market
Shares outstanding
58.31M
Market cap
$783.11M
Enterprise value
$629.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$176.7M
EBITDA
-$174.2M
Free cash flow
-$151.71M
Per share
EPS
-$3.32
Free cash flow per share
-$2.69
Book value per share
$4.29
Revenue per share
$0
TBVPS
$5.12
Balance sheet
Total assets
$288.64M
Total liabilities
$46.71M
Debt
$29.76M
Equity
$241.94M
Working capital
$227.63M
Liquidity
Debt to equity
0.12
Current ratio
11.54
Quick ratio
11.14
Net debt/EBITDA
0.88
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-57.2%
Return on equity
-68.5%
Return on invested capital
-113.7%
Return on capital employed
-66.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DYN stock price

How has the Dyne Therapeutics stock price performed over time
Intraday
5%
1 week
6.08%
1 month
16.18%
1 year
208.03%
YTD
15.88%
QTD
16.58%

Financial performance

How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$180.64M
Net income
-$176.7M
Gross margin
N/A
Net margin
N/A
DYN's operating income is down by 12% YoY and by 6% QoQ
DYN's net income is down by 11% YoY and by 5% QoQ

Growth

What is Dyne Therapeutics's growth rate over time

Valuation

What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
3.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is down by 7% year-on-year and by 2.8% since the previous quarter
The price to book (P/B) is 42% higher than the last 4 quarters average of 2.2
The equity has contracted by 28% YoY and by 4.1% from the previous quarter

Efficiency

How efficient is Dyne Therapeutics business performance
The return on equity has dropped by 68% year-on-year and by 15% since the previous quarter
DYN's return on invested capital has dropped by 63% year-on-year and by 28% since the previous quarter
The company's return on assets has shrunk by 56% YoY and by 13% QoQ

Dividends

What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DYN.

Financial health

How did Dyne Therapeutics financials performed over time
The company's total assets fell by 26% YoY and by 6% QoQ
Dyne Therapeutics's current ratio has decreased by 22% YoY but it has increased by 22% from the previous quarter
The debt is 88% smaller than the equity
The equity has contracted by 28% YoY and by 4.1% from the previous quarter
Dyne Therapeutics's debt to equity has increased by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.